
|Articles|March 12, 2014
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
How Immunotherapies are Changing the Treatment of Melanoma
Author(s)Harriet Kluger, MD
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Read more about ipilimumab, nivolumab, and other immunotherapies being looked at in melanoma > >
Articles in this issue
over 11 years ago
The Outlook for CAR-Modified T Cellsover 11 years ago
B-Cell Malignancies Faring Well With Immunotherapiesover 11 years ago
Update on Immunotherapy and Targeted Combination Therapiesover 11 years ago
Progress Made With PD-L1 as Predictive Biomarkerover 11 years ago
Oncolytic Viral Therapies About to Spreadover 11 years ago
The Future of Immunotherapy Treatments in Lung Cancerover 11 years ago
Checking in on Checkpoint Inhibitors






































